PAPER Ku LJ, Pai MC
SEARCH RESULTS
330059 RESULTS
PAPER Honda H, Terada S, Sato S, Oshima E, Ikeda C, Nagao S, Yokota O, Uchitomi Y
Subjective depressive mood and regional cerebral blood flow in mild Alzheimer's disease.
Int Psychogeriatr. 2014 May;26(5):817-23. Epub 2014 Jan 16 PubMed: 24429060PAPER Carson VB
You or someone you love has just received the diagnosis of Alzheimer's-what next-the memory cafe.
Caring. 2013 Oct;32(8):47. PubMed: 24428046PAPER Hagiwara Y, Yanagisawa T, Atsumi C, Maki F, Shimizu T, Hasegawa Y
[A case report of cerebral amyloid angiopathy-related inflammation treated with cyclophosphamide].
Rinsho Shinkeigaku. 2014;54(1):46-51. PubMed: 24429648PAPER Bailey RM, Howard J, Knight J, Sahara N, Dickson DW, Lewis J
Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model.
Mol Neurodegener. 2014 Jan 15;9:8. PubMed: 24428919PAPER L'Episcopo F, Tirolo C, Caniglia S, Testa N, Morale MC, Serapide MF, Pluchino S, Marchetti B
Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease.
J Mol Cell Biol. 2014 Feb;6(1):13-26. Epub 2014 Jan 14 PubMed: 24431301PAPER Accardi MV, Daniels BA, Brown PM, Fritschy JM, Tyagarajan SK, Bowie D
Mitochondrial reactive oxygen species regulate the strength of inhibitory GABA-mediated synaptic transmission.
Nat Commun. 2014;5:3168. PubMed: 24430741PAPER Gil-Mohapel J, Brocardo PS, Christie BR
The role of oxidative stress in Huntington's disease: are antioxidants good therapeutic candidates?
Curr Drug Targets. 2014 Apr;15(4):454-68. PubMed: 24428525PAPER Kurt TD, Bett C, Fernández-Borges N, Joshi-Barr S, Hornemann S, Rülicke T, Castilla J, Wüthrich K, Aguzzi A, Sigurdson CJ
Prion transmission prevented by modifying the β2-α2 loop structure of host PrPC.
J Neurosci. 2014 Jan 15;34(3):1022-7. PubMed: 24431459PAPER Mays CE, Kim C, Haldiman T, van der Merwe J, Lau A, Yang J, Grams J, Di Bari MA, Nonno R, Telling GC, Kong Q, Langeveld J, McKenzie D, Westaway D, Safar JG
Prion disease tempo determined by host-dependent substrate reduction.
J Clin Invest. 2014 Feb 3;124(2):847-58. Epub 2014 Jan 16 PubMed: 24430187PAPER Arenas E
Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson's disease.
J Mol Cell Biol. 2014 Feb;6(1):42-53. Epub 2014 Jan 14 PubMed: 24431302PAPER Brashear A, Ozelius LJ, Sweadner KJ
ATP1A3 mutations: what is the phenotype?
Neurology. 2014 Feb 11;82(6):468-9. Epub 2014 Jan 15 PubMed: 24431297PAPER Pilleri M, Antonini A
Novel levodopa formulations in the treatment of Parkinson's disease.
Expert Rev Neurother. 2014 Feb;14(2):143-9. Epub 2014 Jan 13 PubMed: 24428803SNCA (α-synuclein)
ALZPEDIA Point mutations in the α-synuclein gene (SNCA), as well as duplication or triplication of wild-type SNCA, cause autosomal-dominant Parkinson’s disease. α-synuclein is abundantly expressed in the nervous system. In neurons, the protein is primarily localiz
2014 Budget Expands Alzheimer’s Funding
COMMUNITY NEWS 2014-01-17 Community News The 2014 U.S. budget, passed by Congress and signed into law by President Obama on January 16, contains some good news for Alzheimer’s researchers, with an additional $80 million earmarked to the National Institute on Aging, according to go
Current Filters
No filters selected